Optimizing adjuvant endocrine therapy for postmenopausal breast cancer: the modified CYP2D6 genotype-based modeling analyses

被引：0
|
作者：
Di, G. H. [1 ]
Shao, Z. M. [1 ]
Yu, K. D. [1 ]
机构：
[1] Fudan Univ, Canc Hosp, Shanghai 200433, Peoples R China
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70445-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [1] Tailoring Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A CYP2D6 Multiple-Genotype-Based Modeling Analysis and a Validation
    Yu, K-D
    Shao, Z-M
    CANCER RESEARCH, 2010, 70
  • [2] Tailoring Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A CYP2D6 Multiple-Genotype-Based Modeling Analysis and Validation
    Yu, Ke-Da
    Huang, A-Ji
    Shao, Zhi-Ming
    PLOS ONE, 2010, 5 (12):
  • [3] Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer:: A modeling analysis
    Punglia, Rinaa S.
    Burstein, Harold J.
    Winer, Eric P.
    Weeks, Jane C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (09): : 642 - 648
  • [4] CYP2D6 Genotype Should Not Be Used to Determine Endocrine Therapy in Postmenopausal Breast Cancer Patients
    Rae, J. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 181 - 184
  • [5] Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis
    Gurwitz, David
    Newman, William
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (18)
  • [6] Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis
    Chlebowski, Rowan T.
    Col, Nananda
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (18): : 1331 - 1332
  • [7] Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis - Response
    Punglia, Rinaa S.
    Burstein, Harold J.
    Winer, Eric P.
    Weeks, Jane C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (18): : 1332 - 1333
  • [8] Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis - Response
    Hayes, Daniel F.
    Stearns, Vered
    Rae, James
    Flockhart, David
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (18) : 1333 - 1334
  • [9] CYP2D6 Genotype Should Not Be Used for Deciding About Tamoxifen Therapy in Postmenopausal Breast Cancer
    Rae, James M.
    Regan, Meredith
    Leyland-Jones, Brian
    Hayes, Daniel F.
    Dowsett, Mitch
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (21) : 2753 - 2755
  • [10] CYP2D6 Genotype and Adjuvant Tamoxifen
    Berry, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (02) : 138 - 140
12345